Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study

Executive Summary

Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.


Related Content

Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis
Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter
Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?
Allergan’s RetroSense Buy Marks Move Into Gene Therapy
Allergan Sees Growth From New Launches, Not Big M&A
3Q EARNINGS: Will Actavis, CEO Saunders continue deal streak?
BioNotebook: Deals from Five Prime/GSK, Actavis/Rhythm, Apricus/Forendo; a DARPA collaboration and IPO news
Tranzyme refocus failure confirmed as TZP-102 crashes again
US "Black box" warnings for metoclopramide-containing drugs
J&J Agrees To Propulsid Settlement


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts